MedImmune to Buy Amgen Colorado Facility?

Quote












C'mon peeps. There's good and bad and in-between and whiners in every organization. Ya'll are falling into the latter category.

Congrats to those Amgenex'ers who have landed on their feet at LakeCentre (NKA: BMC). Please take the best of what you learned at Amgen, grow it at Medi, and leave the bad behind. Take an inward look and improve yourself. Make BMC a success, and it's good for patients and good for the local job market.
 






anonymous said:
C'mon peeps. There's good and bad and in-between and whiners in every organization. Ya'll are falling into the latter category.

Congrats to those Amgenex'ers who have landed on their feet at LakeCentre (NKA: BMC). Please take the best of what you learned at Amgen, grow it at Medi, and leave the bad behind. Take an inward look and improve yourself. Make BMC a success, and it's good for patients and good for the local job market.
Click to expand...

Hey, finally a grown up! Dispense with the snarky comments are realize that all of us with a passion for biotech are hard working, and dedicated professionals with some great experience to offer. I want to see this plant and the BMC team succeed and prosper. I wish them well.
 






I want to see the plant succeed again too. I spent almost 20 years there. Which is why hiring who they hired is such a disappointment. Some very bad choices. And unfortunately the drug isn't going to compete. It's hardly even a competitor.
 






anonymous said:
I want to see the plant succeed again too. I spent almost 20 years there. Which is why hiring who they hired is such a disappointment. Some very bad choices. And unfortunately the drug isn't going to compete. It's hardly even a competitor.
Click to expand...
Sounds like you are mad that you weren't selected as a leader? The drug alone is late to the dance but in the end it is all about combinations, combinations.
 






Then you need to look at the clinical trial data. There was just an article on that very topic. AZ has around half of what BMS and Merck have. They are way out front. These things don't fund themselves. They have too much of a lead time and we are too far behind.
 












Nice thought but Peg is here. It's not good with Peg here. Watch what you say and watch your back. This is bad Amgen.

anonymous said:
C'mon peeps. There's good and bad and in-between and whiners in every organization. Ya'll are falling into the latter category.

Congrats to those Amgenex'ers who have landed on their feet at LakeCentre (NKA: BMC). Please take the best of what you learned at Amgen, grow it at Medi, and leave the bad behind. Take an inward look and improve yourself. Make BMC a success, and it's good for patients and good for the local job market.
Click to expand...
 






anonymous said:
Then you need to look at the clinical trial data. There was just an article on that very topic. AZ has around half of what BMS and Merck have. They are way out front. These things don't fund themselves. They have too much of a lead time and we are too far behind.
Click to expand...
Wow, Medi/AZ must be really bothering you. BMS and Merck are way out front as monotherapy but in the end people will look back and say "why didn't Merck and BMS understand it was all about combination therapy"? Then Merck and their trial lawyer CEO will resort to layoffs (which they are very good at) and BMS will get swallowed up by some Chinese investment group. Which will you fall under, the guy having to update his resume or having to learn Chinese?
 






Both Merck and BMS have combination trials running. No idea what you are taking about.

anonymous said:
Wow, Medi/AZ must be really bothering you. BMS and Merck are way out front as monotherapy but in the end people will look back and say "why didn't Merck and BMS understand it was all about combination therapy"? Then Merck and their trial lawyer CEO will resort to layoffs (which they are very good at) and BMS will get swallowed up by some Chinese investment group. Which will you fall under, the guy having to update his resume or having to learn Chinese?
Click to expand...
 






And I work for Medimmune. I would like it to stay that way but everything that the investment analysts are saying doesn't paint a pretty picture. What you are saying simply isn't the case. Both other companies have far more clinical trials in both mono and combo. I am hoping that I was missing something but that doesn't seem to be it. AZ is way off their crazy financial targets and that usually spells dramatic changes. It's not hard to find the data and opinions. It's all out there.
 






anonymous said:
And I work for Medimmune. I would like it to stay that way but everything that the investment analysts are saying doesn't paint a pretty picture. What you are saying simply isn't the case. Both other companies have far more clinical trials in both mono and combo. I am hoping that I was missing something but that doesn't seem to be it. AZ is way off their crazy financial targets and that usually spells dramatic changes. It's not hard to find the data and opinions. It's all out there.
Click to expand...
We'll see how it plays out. IO is really all that AZ/MEDI has. If they bailout, where do they go next? Perhaps it will be a sale.
 






anonymous said:
And I work for Medimmune. I would like it to stay that way but everything that the investment analysts are saying doesn't paint a pretty picture. What you are saying simply isn't the case. Both other companies have far more clinical trials in both mono and combo. I am hoping that I was missing something but that doesn't seem to be it. AZ is way off their crazy financial targets and that usually spells dramatic changes. It's not hard to find the data and opinions. It's all out there.
Click to expand...
Just keep focused on your submission. There are 71 checkpoint inhibitors in preclinical or clinical development. Medi is #4. You will be fine.
 
























It's funny that in every organization there are negative people. If you don't believe in the pipeline and leadership within Medi then just leave. We can replace you with folks that are more interested in moving the pipeline forward.
 






anonymous said:
And I work for Medimmune. I would like it to stay that way but everything that the investment analysts are saying doesn't paint a pretty picture. What you are saying simply isn't the case. Both other companies have far more clinical trials in both mono and combo. I am hoping that I was missing something but that doesn't seem to be it. AZ is way off their crazy financial targets and that usually spells dramatic changes. It's not hard to find the data and opinions. It's all out there.
Click to expand...
BMS and Merck will win the battle but not the war
 












Top Bottom
Back
Quote